Lisata Therapeutics Inc

Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lisata Therapeutics advances certepetide, poised to revolutionize cancer treatment

Lisata Therapeutics' Q1 2024 performance reflects prudent financial management and promising advancements in certepetide's clinical development
Despite challenges in meeting trial milestones and reshaping oncology standards, the company's strengths in regulatory support and safety profile offer a competitive edge
Opportunities lie in certepetide's potential to redefine cancer treatment paradigms, with successful trials paving the way for market leadership and global expansion

Lisata Therapeutics reports improved Q2 performance and advances in oncology

Lisata Therapeutics showed improved financial performance in Q2 2024 with reduced operating expenses and a strong cash position.
The progress on Certepetide underscores the company's commitment to innovative R&D and potential breakthroughs in advanced solid tumor treatments.
While facing challenges such as net losses and competitive pressures, Lisata Therapeutics has opportunities to drive growth through strategic partnerships and clinical trial advancements.

Lisata Therapeutics advances certepetide in cancer and endometriosis treatments

Lisata Therapeutics showcased progress in certepetide's cancer treatment and endometriosis exploration, despite a net loss in Q3 2024. The company faces challenges in aligning market perception with its promising pipeline but has opportunities for growth through ongoing trials and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a research collaboration with Haystack Oncology using Haystack's MRD technology to evaluate the efficacy of its investigational pancreatic cancer therapy certepetide. Per the research agreement, Lisata will deploy the Haystack MRD technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.

Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research

BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, and Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced a research collaboration. Lisata will deploy the highly sensitive Haystack MRD™ technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.

Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why

Lisata Therapeutics Inc (NASDAQ:LSTA) said it has completed enrollment in its Phase 2a BOLSTER trial for certepetide, a promising investigational treatment for first-line cholangiocarcinoma (CCA). The BOLSTER trial, a Phase 2a double-blind, placebo-controlled study conducted across multiple centers in the United States, evaluates certepetide in combination with standard-of-care versus standard-of-care alone for patients with first-line CCA.

Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer

Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to BOLSTER trial BASKING RIDGE, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced today the early completion of enrollment in its Phase 2a BOLSTER trial evaluating certepetide (formerly LSTA1), Lisata's investigational product, as a treatment for first-line cholangiocarcinoma (“CCA”).

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck talked with Proactive about encouraging preclinical results for their drug candidate, certepetide, in treating intrahepatic cholangiocarcinoma, otherwise known as bile duct cancer. Preclinical results support certepetide's potential to enhance chemotherapy and immunotherapy, which is expected to translate into improved patient survival.

Lisata's certepetide showing promising early results as cholangiocarcinoma treatment – ICYMI

Lisata Therapeutics Inc (NASDAQ:LSTA) has unveiled encouraging preclinical results for its drug candidate, certepetide, in intrahepatic cholangiocarcinoma, a cancer found inside the bile ducts. The results, presented at the 2024 Cholangiocarcinoma Foundation Annual Conference, support advancing clinical development efforts for the drug.

Lisata Therapeutics shares promising pre-clinical data

Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss a recent milestone for the company: the completion of patient enrollment in the pancreatic cancer cohort of its Phase 1b/2a CENDIFOX trial.   The trial is evaluating the safety and efficacy of certepetide (formerly LSTA1) in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.

Lisata Therapeutics CEO discusses enrollment milestone for pancreatic cancer trial

Lisata Therapeutics Inc (NASDAQ:LSTA) announced it has completed enrollment in the pancreatic cancer cohort of its Phase 1b/2a CENDIFOX trial. The trial evaluates the safety and efficacy of certepetide (formerly LSTA1) in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.

Lisata Therapeutics completes pancreatic cancer cohort enrollment in CENDIFOX trial

Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech companies over the past three years as they seek recognition in a market that has performed ‘a 180' turn since the peak of Covid vaccines interest in the sector in 2021. Risk capital has been sidelined during this politically and economically volatile period, not just in life sciences, but across microcap markets internationally.

How does Lisata Therapeutics have a negative enterprise value?

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June:

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

Lisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for its lead investigational product, certepetide, in pancreatic cancer. The waiver, recommended by the Paediatric Committee (PDCO) and granted by the EMA, confirms that pediatric studies for certepetide in pancreatic cancer are not required.

Lisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancer

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has reached agreement with the European Medicines Agency (the “EMA”) on a Paediatric Investigation Plan (“PIP”) for Lisata's lead investigational product, certepetide (formerly LSTA1), in pancreatic cancer.

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer Kristen Buck – Executive Vice President-Research and Development and Chief Medical Officer James Nisco – Chief Accounting Officer Conference Call Participants Sara Nik – H.C. Wainwright Will Hidell – Brookline Capital Markets Pete Enderlin – MAZ Partners Steve Brozak – WBB securities Robert Sassoon – Water Tower Research Robert LeBoyer – Noble Capital Markets Operator Welcome to the Lisata Therapeutics First Quarter 2024 Financial Results and Business Update Conference Call.

Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript

Lisata Therapeutics Inc (NASDAQ:LSTA) has ended its first quarter of 2024 with nearly $43.3 million in cash to fund its tumor-fighting drug development activities well into the coming year. CEO David Mazzo told shareholders that the company is off to a strong start to 2024, with Phase 2b ASCEND trial top-line data expected in fourth quarter.

Lisata Therapeutics reports strong 1Q performance, cash to support operations into 2026

Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for three months ended March 31, 2024, on Thursday, May 9, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation (“ODD”) to LSTA1, the Company's lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults. LSTA1 recently received Rare Pediatric Disease Designation for osteosarcoma, as announced by the Company on March 21, 2024.

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will participate in the following events in April:

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.

Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma

BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Rare Pediatric Disease Designation (“RPDD”) to LSTA1, the Company's lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults.

News for Lisata Therapeutics Inc Stock (LSTA)